Key Highlights

  • Therapeutics revenue surged 55% year over year.
  • DNA synthesis and protein solutions segment expanded 28% YoY.
  • Gross margin now stands above 50% while cash totals $172 million and debt is nil.

Twist Bioscience delivered notable top‑line growth, with therapeutics revenue climbing 55% and its DNA synthesis and protein solutions segment up 28% YoY. The company also highlighted a gross margin that now exceeds 50% and projected adjusted EBITDA to break even in the fourth quarter if execution holds.

By the Numbers

Twist Bioscience’s financial snapshot shows a solid balance sheet featuring $172 million in net cash and zero debt. The firm’s profitability metric improved, with gross margin now surpassing the 50% threshold, underscoring efficient operations in a capital‑intensive market. These fundamentals support management’s confidence in meeting near‑term earnings targets.

Segment Detail

The DNA synthesis and protein solutions segment, the company’s growth engine, recorded a 28% year‑over‑year increase, reflecting strong demand for its semiconductor‑based platform. Therapeutics revenue, another key pillar, accelerated 55% as the company leverages its wet‑lab capabilities for Amazon Biodiscovery, an AI‑driven drug‑discovery service. The partnership with Amazon places Twist Bioscience at the forefront of integrating synthetic biology with cloud‑based artificial intelligence.

Guidance

Management indicated that, provided current execution trends continue, adjusted EBITDA is expected to reach breakeven levels in the fourth quarter. The outlook aligns with recent strategic collaborations and the firm’s cash‑rich, debt‑free position, suggesting sufficient runway to sustain its growth trajectory without additional financing. Investors will monitor the impact of the Amazon Biodiscovery partnership on future revenue streams.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.